Passamonti Francesco
Passamonti Francesco
University of Insubria, Varese, Italy
Verified email at
Cited by
Cited by
A gain-of-function mutation of JAK2 in myeloproliferative disorders
R Kralovics, F Passamonti, AS Buser, SS Teo, R Tiedt, JR Passweg, ...
New England Journal of Medicine 352 (17), 1779-1790, 2005
New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment
F Cervantes, B Dupriez, A Pereira, F Passamonti, JT Reilly, E Morra, ...
Blood, The Journal of the American Society of Hematology 113 (13), 2895-2901, 2009
Efficacy and safety of low-dose aspirin in polycythemia vera
R Landolfi, R Marchioli, J Kutti, H Gisslinger, G Tognoni, C Patrono, ...
New England Journal of Medicine 350 (2), 114-124, 2004
Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making
L Malcovati, MGD Porta, C Pascutto, R Invernizzi, M Boni, E Travaglino, ...
Journal of Clinical Oncology 23 (30), 7594-7603, 2005
DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and …
N Gangat, D Caramazza, R Vaidya, G George, K Begna, S Schwager, ...
Journal of Clinical Oncology 29 (4), 392-397, 2011
Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet
T Barbui, G Barosi, G Birgegard, F Cervantes, G Finazzi, M Griesshammer, ...
Journal of Clinical Oncology 29 (6), 761, 2011
A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and …
F Passamonti, F Cervantes, AM Vannucchi, E Morra, E Rumi, A Pereira, ...
Blood, The Journal of the American Society of Hematology 115 (9), 1703-1708, 2010
Ruxolitinib versus standard therapy for the treatment of polycythemia vera
AM Vannucchi, JJ Kiladjian, M Griesshammer, T Masszi, S Durrant, ...
New England Journal of Medicine 372 (5), 426-435, 2015
Cardiovascular events and intensity of treatment in polycythemia vera
R Marchioli, G Finazzi, G Specchia, R Cacciola, R Cavazzina, D Cilloni, ...
N Engl J Med 368, 22-33, 2013
Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA …
MA Sanz, FL Coco, G Martın, G Avvisati, C Rayón, T Barbui, ...
Blood, The Journal of the American Society of Hematology 96 (4), 1247-1253, 2000
A randomized clinical trial of high‐intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid …
G Finazzi, R Marchioli, V Brancaccio, P Schinco, F Wisloff, J Musial, ...
Journal of Thrombosis and Haemostasis 3 (5), 848-853, 2005
Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study
A Tefferi, E Rumi, G Finazzi, H Gisslinger, AM Vannucchi, F Rodeghiero, ...
Leukemia 27 (9), 1874-1881, 2013
Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia
F Passamonti, E Rumi, E Pungolino, L Malabarba, P Bertazzoni, ...
The American journal of medicine 117 (10), 755-761, 2004
CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons
A Tefferi, TL Lasho, CM Finke, RA Knudson, R Ketterling, CH Hanson, ...
Leukemia 28 (7), 1472-1477, 2014
Polycythemia vera: the natural history of 1213 patients followed for 20 years
GIS Policitemia
Annals of Internal Medicine 123 (9), 656-664, 1995
CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59
J Golay, M Lazzari, V Facchinetti, S Bernasconi, G Borleri, T Barbui, ...
Blood, The Journal of the American Society of Hematology 98 (12), 3383-3389, 2001
Development and validation of an International Prognostic Score of thrombosis in World Health Organization–essential thrombocythemia (IPSET-thrombosis)
T Barbui, G Finazzi, A Carobbio, J Thiele, F Passamonti, E Rumi, ...
Blood, The Journal of the American Society of Hematology 120 (26), 5128-5133, 2012
Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study
T Barbui, J Thiele, F Passamonti, E Rumi, E Boveri, M Ruggeri, ...
J Clin Oncol 29 (23), 3179-3184, 2011
Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for …
G Barosi, RA Mesa, J Thiele, F Cervantes, PJ Campbell, S Verstovsek, ...
Leukemia 22 (2), 437-438, 2008
Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the …
T Barbui, G Barosi, A Grossi, L Gugliotta, LN Liberato, M Marchetti, ...
haematologica 89 (2), 215-232, 2004
The system can't perform the operation now. Try again later.
Articles 1–20